These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
479 related articles for article (PubMed ID: 30355587)
1. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587 [TBL] [Abstract][Full Text] [Related]
2. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000 [TBL] [Abstract][Full Text] [Related]
3. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612 [TBL] [Abstract][Full Text] [Related]
4. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062 [TBL] [Abstract][Full Text] [Related]
7. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer. Trenti E; Pycha S; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Spedicato GA; Vjaters E; Degener S; Pycha A; D'Elia C Cancer Cytopathol; 2020 May; 128(5):341-347. PubMed ID: 31977131 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer. Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670 [TBL] [Abstract][Full Text] [Related]
9. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer. Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma. Pycha S; Trenti E; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; D'Elia C World J Urol; 2023 May; 41(5):1323-1328. PubMed ID: 36929411 [TBL] [Abstract][Full Text] [Related]
11. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252 [TBL] [Abstract][Full Text] [Related]
12. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. Hurle R; Casale P; Saita A; Colombo P; Elefante GM; Lughezzani G; Fasulo V; Paciotti M; Domanico L; Bevilacqua G; Maffei D; Diana P; Frego N; Sandri MT; Maura F; Morenghi E; Buffi NM; Guazzoni G; Lazzeri M World J Urol; 2020 Sep; 38(9):2215-2220. PubMed ID: 31691083 [TBL] [Abstract][Full Text] [Related]
13. Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor. Haas M; Kriegmair MC; Breyer J; Sikic D; Wezel F; Roghmann F; Brehmer M; Wirtz RM; Jarczyk J; Erben P; Bahlinger V; Goldschmidt F; Fechner G; Chen J; Paxinos E; Bates M; Zengerling F; Bolenz C; Burger M; Hartmann A; Eckstein M BJU Int; 2024 May; ():. PubMed ID: 38717014 [TBL] [Abstract][Full Text] [Related]
14. The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors. Smrkolj T; Cegovnik Primozic U; Fabjan T; Sterpin S; Osredkar J Radiol Oncol; 2020 Dec; 55(2):196-202. PubMed ID: 33764701 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739 [TBL] [Abstract][Full Text] [Related]
16. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer. Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142 [TBL] [Abstract][Full Text] [Related]
17. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Lu X; Simon IM; Campbell SA; Bates MP; Higuchi RG; Witjes JA Eur Urol Oncol; 2021 Feb; 4(1):93-101. PubMed ID: 33004290 [TBL] [Abstract][Full Text] [Related]
18. Urine cell-based DNA methylation classifier for monitoring bladder cancer. van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012 [TBL] [Abstract][Full Text] [Related]
19. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project. Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893 [TBL] [Abstract][Full Text] [Related]
20. Xpert® bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results. D'Elia C; Trenti E; Krause P; Pycha A; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Palermo M; Spedicato GA; Holl S; Pycha A Ther Adv Urol; 2022; 14():17562872221090320. PubMed ID: 35450126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]